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Lanning NJ, VanOpstall C, Goodall ML, MacKeigan JP, Looyenga BD. LRRK2 deficiency impairs trans-Golgi to lysosome trafficking
and endocytic cargo degradation in human renal proximal tubule
epithelial cells. Am J Physiol Renal Physiol 315: F1465–F1477,
2018. First published August 8, 2018; doi:10.1152/ajprenal.00009.
2018.—Defects in vesicular trafficking underlie a wide variety of
human diseases. Genetic disruption of leucine-rich repeat kinase 2
(LRRK2) in rodents results in epithelial vesicular trafficking errors
that can also be induced by treatment of animals with LRRK2 kinase
inhibitors. Here we demonstrate that defects in human renal cells
lacking LRRK2 phenocopy those seen in the kidneys of Lrrk2 knockout mice, characterized by accumulation of intracellular waste vesicles and fragmentation of the Golgi apparatus. This phenotype can be
recapitulated by knockdown of N-ethylmaleimide-sensitive factor,
which physically associates with LRRK2 in renal cells. Deficiency in
either protein leads to a defect in trans-Golgi to lysosome protein
trafficking, which compromises the capacity of lysosomes to degrade
endocytic and autophagic cargo. In contrast, neither bulk endocytosis
nor autophagic flux are impaired when LRRK2 is acutely knocked
down in normal immortalized human kidney (HK2) cells. These data
collectively suggest that the primary renal defect caused by LRRK2
deficiency is in protein trafficking between the Golgi apparatus and
late endosome/lysosome, which leads to progressive impairments in
lysosomal function.
Golgi apparatus; LRRK2; lysosome; NSF; vesicle trafficking

INTRODUCTION

Activating mutations to human LRRK2 are now well-established drivers of Parkinson’s disease (PD) (30, 39). Because
most, if not all, of these mutations increase the kinase activity
of LRRK2, pharmacologic inhibition of this enzyme has been
an attractive target for PD therapy (16, 34). Two limiting
factors for such drugs are their ability to penetrate the brain and
the potential for dose-limiting side effects on peripheral tissues. Though the former limitation has largely been overcome,
animal studies with brain penetrant LRRK2 inhibitors have
demonstrated that chronic inhibition of LRRK2 is associated
with toxicity to the pulmonary epithelia (10, 14, 18). This
toxicity is phenotypically similar to defects seen in Lrrk2
knockout mice, suggesting a role of LRRK2 in normal Type II
pneumocyte function (14, 38). Perhaps surprising, however, is
Address for reprint requests and other correspondence: B. D. Looyenga,
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the relative lack of toxicity in the kidneys of drug-treated
animals given that both Lrrk2 knockout mice and rats display
profound renal dysfunction associated with cellular defects in
vesicular trafficking and lysosomal function (4, 38). Whether
this points to distinct enzymatic roles for LRRK2 in pulmonary
and renal epithelia or a lack of cellular exposure to LRRK2
inhibitors in the kidney is unclear.
The effect of LRRK2 kinase inhibition in the kidney is also
of significance based on studies that demonstrate LRRK2 is
chromosomally amplified and overexpressed in papillary renal
cell carcinoma (pRCC) (2, 23). Perturbation of LRRK2 expression in human pRCC cell lines results in cell cycle arrest and
selective inhibition of key cell signaling pathways, most likely
via the disruption of signal transduction by growth factor
receptors. Other studies have uncovered LRRK2 overexpression or mutation in a variety of solid tumors, as well as
epidemiological evidence that PD-associated mutations to
LRRK2 (G2019S) increase the risk of several nonskin cancers
(1, 20, 33). Together these data suggest that LRRK2 kinase
inhibitors may potentially be repurposed for cancer therapy,
providing they can be used for a relatively short period of time
to avoid peripheral toxicity to the lung. Understanding the
molecular role of LRRK2 in cancer and normal tissues is
therefore of paramount importance.
Most current literature supports a role for LRRK2 in vesicular trafficking processes downstream of endocytosis, such as
autophagy and cargo sorting (3, 24, 26, 35). Precisely where in
these processes LRRK2 is involved is less clear, as it appears
to interact physically with and/or phosphorylate a number of
protein substrates known to be involved in vesicular trafficking. Most prominent among these substrates are Rab family
GTPases, particularly those involved in late endosomal sorting
(6, 15, 24, 36). Given that the renal and pulmonary phenotypes
of Lrrk2⫺/⫺ mice include the epithelial accumulation of intracellular vesicles containing undigested waste, it seems probable that LRRK2 regulates late endosomal compartment homeostasis via its interactions with Rab family GTPases and other
vesicular trafficking proteins (19, 38). The central role of this
compartment in endocytic cargo sorting may also explain the
propensity for amplification or mutation of LRRK2 across
several solid tumor types, as it is now well established that
alterations to endosomal trafficking machinery play an important role in cancer development (12).
In addition to its interactions with Rab proteins, LRRK2 has
also been shown to interact with N-ethylmaleimide-sensitive
fusion (NSF) protein, which functions as an ATP-dependent
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disassembly factor for cis-SNARE complexes after vesicular
fusion (7, 31). Though this activity of NSF is its most prominent function—and the one implicated in its interaction with
LRRK2—it has also been shown to mediate restacking of
Golgi apparatus fragments into discrete cisternae after the
completion of mitosis, which is necessary for proper vesicular
trafficking between the Golgi apparatus and other cellular
compartments (5, 32). Unlike its SNARE disassembly function, this secondary role for NSF is independent of its ATPase
activity though it appears to be conserved in metazoans as
simple as Drosophila (28). Whether interactions between
LRRK2 and NSF also impact Golgi integrity and sorting
between the Golgi and other compartments is unknown. In this
study we address this issue in the context of human renal
epithelial cells, and present findings that suggest the vesicular
trafficking defects previously identified in LRRK2-deficient
cells are centrally related to disorganization of the Golgi
apparatus.
MATERIALS AND METHODS

Antibodies and reagents. Rabbit monoclonal or polyclonal antibodies for Rab5, Rab7, NSF, LC3B, and STX6 used for immunoblotting
and immunofluorescent staining were purchased from Cell Signaling
Technology (Danvers, MA). The anti-LRRK2 (UDD3), anti-LRRK2
(MJFF2) anti-phospho-LRRK2-S935, anti-GBA, and anti-ARSB rabbit monoclonal antibodies were obtained from Epitomics (Epitomics/
Abcam, Cambridge, MA). The anti-␤-actin and tubulin mouse monoclonal antibodies used for immunoblotting were obtained from SigmaAldrich (Sigma, St. Louis, MO). The anti-V5 epitope mouse
monoclonal antibody and AlexaFluor-conjugated goat secondary antibodies were obtained from Invitrogen/Life Technologies (Thermo
Fisher Scientific, Grand Island, NY). The anti-p62/SQSTM1, EEA1,
LAMP1, and gm130 mouse monoclonal antibodies used for immunofluorescent staining were obtained from Becton Dickinson (BD
Biosciences, San Jose, CA). All antibodies were used at the dilutions
recommended by each manufacturer unless otherwise specified.
All chemical reagents were obtained from Sigma-Aldrich unless
otherwise indicated. The LRRK2 catalytic inhibitor GNE-7915 was
purchased from Selleck Chemicals (Houston, TX) and used at the
indicated concentrations. The LRRK2 inhibitor PFE-475 (PFE06447475) was provided by Dr. Jaclyn Henderson (Pfizer, New York,
NY). Vesicular trafficking cargoes AlexaFluor488-transferrin, AlexaFluor488-dextran, and BZiPAR [rhodamine 110, bis-(CBZ-L-isoleucyl-L-prolyl-L-arginine amide), and dihydrochloride] were purchased
from Invitrogen/Life Technologies and used at the indicated concentrations.
Immunohistochemistry. Murine renal tissues were obtained as a gift
from Dr. Ted Dawson (The Johns Hopkins University, Baltimore,
MD). The tissues were harvested from necropsied Lrrk2⫺/⫺ animals
and wild-type littermates in compliance with approved animal care
guidelines from Johns Hopkins Institutional Animal Care and Use
Committee. Tissues were fixed for ~24 h in 4% paraformaldehyde,
washed with cold phosphate-buffered saline (PBS), and stored at 4°C
in 70% ethanol. The tissues were then dehydrated through graded
ethanols and methyl salicylate and then embedded in paraffin before
sectioning. Kidney sections were cut at 5-m thickness and floated
onto glass slides for drying at 37°C to promote adherence. After
drying, sections were deparaffinized, rehydrated, and stained with
hematoxylin and eosin using a Symphony Automated H&E stainer
(Ventana Medical Systems, Tucson, AZ) in the Van Andel Institute
Core Facility. Images were captured with an ECLIPSE Ci photomicroscope (Nikon Instruments, Melville, NY) at ⫻20 and ⫻40 resolution.

Cell culture. Normal immortalized human kidney (HK2) cells were
purchased from American Type Culture Collection (Manassas, VA)
and maintained in RPMI-1640 medium supplemented with 2 mM
GlutaMAX (Thermo Fisher Scientific) and 10% fetal bovine serum
(FBS). Human embryonic kidney 293FT cells were obtained from
Invitrogen/Life Technologies (Thermo Fisher Scientific) and maintained in standard DMEM with high glucose (4.5 g/l) and 10% FBS.
Both cell lines were incubated in a humidified and sterile tissue
culture incubator at 37°C with 5% CO2 atmosphere. Stable HK2
polyclonal cell lines expressing short hairpin RNAs (shRNAs) were
produced by infecting cells with conditioned viral medium from
293FT producer cells that had been diluted 1:10 in HK2 medium and
supplemented with 8.0 g/ml polybrene. After 48 –72 h incubation,
cells were replated in culture medium containing 2 g/ml puromycin
to select for cells with integrated lentivirus. Because long-term depletion of LRRK2 and NSF (⬎2 wk) results in increased HK2 cell
death, all assays that utilized stable shRNA lines were performed on
freshly selected cells without further passaging or freeze/thaw cycles.
Amino acid starvation of cells was performed by washing them
with Dulbecco’s phosphate-buffered saline (DPBS) and refeeding
with DPBS supplemented with 20 mM HEPES buffer (pH 7.2),
insulin-transferrin-selenium (Thermo Fisher Scientific), 10 mM D-glucose, and 1⫻ RPMI vitamins (Sigma-Aldrich) lacking all amino
acids. To block autophagosome processing by lysosomal acidification,
cells were treated in parallel with bafilomycin A1 (50 nM) along with
amino acid starvation.
Lentiviral vector production. Validated lentiviral shRNA vector
plasmids from The RNA Consortium pLKO.1 collection were obtained from Sigma-Aldrich (Sigma). Each lentiviral plasmid was
transfected into a 10-cm dish containing 1.5 million 293FT cells along
with ViraPower third-generation packaging plasmids (pLP1, pLP2,
and pVSVG; Thermo Fisher Scientific) using standard calcium phosphate precipitation. Medium was changed the following day and
allowed to incubate on cells for 72 h before harvest. The 10 ml of
conditioned medium from each lentiviral vector was removed and
filtered through a 0.4-m syringe filter before freezing at ⫺80°C in
1-ml aliquots.
Immunofluorescence microscopy. Parental HK2 cells or stable
polyclonal cell lines expressing shRNAs were seeded to glass coverslips or glass-bottom 96-well plates (Greiner Bio-One, Monroe, NC)
in culture medium and allowed to adhere overnight under standard
tissue culture conditions. Treatment of cells before fixation and
staining is indicated in each data figure. Cells were fixed with 3.7%
formaldehyde in PBS solution and permeabilized with 0.2% Triton
X-100 on ice. After being blocked in 5% normal goat serum (Sigma)
in PBS solution, the cells were incubated with the indicated primary
antibody diluted in blocking buffer overnight at 4°C. The following
day cells were washed with PBS containing 0.05% Tween 20 (PBST)and stained with AlexaFluor-488 coupled goat anti-rabbit and
AlexaFluor-546 coupled goat anti-mouse secondary antibodies (Invitrogen/Life Technologies) diluted at 1:1,000 in blocking buffer for 1 h
at room temperature. After a second round of washing in PBS-T, the
cells were nuclear counter-stained with DAPI (1 g/ml) and prepared
with gel mounting medium before mounting on glass slides. Epifluorescent images of cells were obtained using a Nikon Ti-E inverted
fluorescence microscope equipped with DAPI, FITC, and Texas Red
filter sets and processed using the NIS Elements software package
(Nikon Instruments). Confocal images were obtained using a Nikon
A1plus-RSi scanning confocal microscope equipped with 403-, 488-,
561-, and 640-nm solid-state lasers and a 32-detector spectral imager
(Nikon Instruments). All images were processed and quantified using
the NIS Elements software package (Nikon Instruments).
Immunoblotting. Cells cultured in 6-well dishes were rinsed with
cold PBS and harvested into 100 l of lysis buffer [20 mM Tris (pH
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium
pyrophosphate, 1 mM sodium glycerophosphate, 1 mM sodium orthovanadate, 0.5% Nonidet P-40 (NP40), 0.1% Brij35, 0.1% sodium
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deoxycholate] supplemented with mammalian cell protease inhibitor
cocktail (Sigma-Aldrich). Each lysate was homogenized by brief
sonication at 30% power on ice and then cleared by centrifugation at
10,000 relative centrifugal forces (rcf) for 5 min at 4°C. Concentration
of each lysate was determined by Bradford assay along with a twofold
serial dilution of 10 mg/ml BSA to generate a standard curve. Equal
amounts of protein lysate (20 –50 g) were separated by reducing
polyacrylamide gel electrophoresis and transferred overnight to nitrocellulose membrane using a traditional wet transfer apparatus (TE62
model; Hoefer, Holliston, MA). The blots were blocked with 3%
nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20
(TBST) and then probed overnight at 4°C with primary antibodies
diluted to the manufacturer’s specification. After unbound primary
antibody was washed off, the membranes were incubated for 1 h at
room temperature with goat anti-rabbit-IRDyeTM800 and goat antimouse-IRDyeTM680 secondary antibodies (Li-Cor, Lincoln, NE) and
then imaged with an Odyssey scanner (Li-Cor). Images were processed with the Odyssey Infrared ImaginingSystem software (version
3.0.25) to ensure that signal was in the linear range of photon
detection before export in TIFF format.
Immunoprecipitation. Cells cultured in 10-cm dishes were rinsed
with cold PBS and harvested into 0.4 ml of immunoprecipitation
buffer [50 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 5 mM sodium pyrophosphate, 10 mM sodium glycerophosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 0.1%
NP40, 10% glycerol] supplemented with mammalian cell protease
inhibitor cocktail and N-ethylmaleimide when indicated (Sigma-Aldrich). The lysates were homogenized by shearing through a 25-gauge
needle on ice and cleared by centrifugation at 10,000 rcf for 5 min at
4°C. Lysates were quantified by Bradford assay as above, and equal
protein amounts (0.5–1 mg) were incubated for 1 h at 4°C with
anti-LRRK2-UDD3 antibody (Abcam) diluted 1:100 in a final volume
of 1 ml. Affinity complexes were precipitated by addition of 50 l of
equilibrated protein-G agarose beads (Invitrogen/Life Technologies)
and incubation at 4°C with rotation for an additional hour. Bead
pellets were washed three times with 0.9-ml volumes of buffer and
eluted by boiling in 80 l of 2⫻ Laemmli Buffer [120 mM Tris (pH
6.8), 4% SDS, 20% glycerol, 0.02% bromophenol blue, 50 mM DTT].
Transmission electron microscopy. HK2 stable cell lines grown in
10-cm dishes were trypsinized, pelleted, washed in PBS, and resuspended in 2% glutaraldehyde for fixation (Sigma). The cell pellets
were then embedded in 2% agarose, postfixed in osmium tetroxide,
and dehydrated with graded acetones. Samples were embedded in
Poly/Bed 812 resin and polymerized at 60°C for 24 h. Ultrathin
sections (70 nm) were generated with a Power Tome XL (Boeckeler
Instruments, Tucson, AZ) and placed on copper grids. Cells were
examined using a JEOL 100C ⫻ transmission electron microscope at
100 kV (Tokyo, Japan). Electron microscopy services were performed
by the Michigan State University Center for Advanced Microscopy
(East Lansing, MI).
EdU cell proliferation assay. Identification of proliferating cells
found in the S-phase of the cell cycle was performed using the
Click-iT EdU AlexaFluor488 imaging kit from Invitrogen/Life Technologies. In this assay the thymidine analog 5-ethynyl-deoxyuridine
(EdU) was pulsed to cells at 10 M for 1 h under normal cell culture
conditions, after which time the cells were fixed and stained for EdU
incorporation using copper (I) catalyzed click chemistry. This assay
covalently couples AlexaFluor488 to EdU, thereby labeling the nuclei
of cells that were actively undergoing DNA replication during the 1-h
pulse. The mild conditions of this assay retain cellular protein stability
and allow for subsequent immunofluorescent staining by standard
methods.
Vesicular trafficking assays. Stable polyclonal HK2 cell lines
expressing shRNAs were plated to 96-well plates at a density of
10,000 cells per well in RPMI-1640 medium with 1% FBS and
allowed to adhere overnight. The following day cells were starved of
serum in basal RPMI-1640 medium for 1 h and then incubated with
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individual substrates for the indicated times before washing with PBS
and fixation with 3.7% formaldehyde in PBS solution. AlexaFluor488-dextran was used at 10 g/ml to monitor bulk phase
endocytosis, whereas AlexaFluor488-transferrin was used at 50 g/ml
to monitor receptor-mediated endocytosis dependent on receptor recycling. At the end of the assay, 96-well plates were assayed at
Ex/Em:488/510 nm in a Synergy H1 multimode plate reader (BioTek,
Winooski, VT). For lysosomal trafficking assays, the fluorogenic
peptide substrate BZiPAR was incubated with live cells at 50 M
concentration ⫾ 30 M dynasore as a negative control for endocytic
uptake. These assays were monitored continuously at Ex/Em:495/520
nm for 30 min in the Synergy H1 multimode plate reader warmed to
37°C with 5% CO2 atmosphere. Fluorescent values from each substrate were normalized to cell number in each well using the CyQuant-NT nuclear dye (Invitrogen/Life Technologies) as a relative
benchmark for cellular abundance. Assays were performed in triplicate and graphed with standard deviations from each assay using the
Prism software package (Mac version 6, GraphPad Software, La Jolla,
CA). Data were best fit to standard linear or hyperbolic curves and
analyzed for significance using Student’s t-test as indicated.
Cellular fractionation. Isolation of distinct organelle populations
from stable polyclonal HK2 cell lines was performed according the
fractionation assay described by Mazzulli, et al. (25). Briefly, cells
were plated to 15-cm dishes at a density of 8 million cells per plate
and allowed to adhere overnight in RPMI-1640 medium containing
10% FBS. The following day cells were washed on ice with cold PBS
and scraped into 1 ml of fractionation buffer [10 mM HEPES (pH
7.4), 1 mM EDTA, 0.25 M sucrose] supplemented with mammalian
cell protease inhibitor cocktail (Sigma). The cells were dounce homogenized on ice with 100 strokes, and the subsequent lysate was
centrifuged at 6,800 rcf for 5 min at 4°C to pellet out the nuclear
fraction and intact cells (P1). Supernatant from this fraction was
removed and centrifuged at 17,000 rcf for 10 min at 4°C to isolate the
lysosomal fraction (P2). Supernatant from the second centrifugation
was again removed and spun a final time at 104,000 rcf in an
ultracentrifuge for 1 h at 4°C to isolate the microsomal fraction
containing endoplasmic reticulum and Golgi-derived vesicles (P3).
Both the P2 and P3 fractions were washed once with fractionation
buffer and then resuspended in 0.1 ml of organelle lysis buffer [20
mM HEPES (pH 7.4), 150 mM sodium chloride, 1 mM EDTA, 1.5
mM magnesium chloride, 50 mM sodium fluoride, 2 mM sodium
orthovanadate, 1% Triton X-100, 10% glycerol] to disrupt organelle
membranes. Protein concentration from each fraction was determined
by Bradford assay as above.
N-acetylglucosaminidase activity assay. The N-acetylglucosaminidase (NAG) activity found in lysosomes and microsomes was assessed using 4-methylumbelliferyl-N-acetyl-␤- D -glucosaminide
(MNDG) as a substrate. Cleavage of the glycosidic bond in this
substrate by lysosomal hexosaminidases releases 4-methylubelliferone, which can be quantified by fluorescence plate reader. Assays
were performed on 0.50 g of total protein from each fraction, which
was diluted in a final volume of 50 l in 250 mM citrate buffer (pH
4.6) containing a saturating concentration of 1 mM MNDG. Fluorescence values at Ex/Em:355/460 nm were measured on a Synergy H1
plate reader (BioTek) at 1-min intervals over a 15-min assay and then
converted to product concentrations using a standard curve of known
4-methylubelliferone concentration. The slope of the linear plot from
each assay was used to determine NAG activity values in
nmol·min⫺1·g⫺1 of lysate. Each assay was performed three times in
triplicate to determine average activity values and the standard deviation of activity in each fraction.
Quantitative RT-PCR. Total RNA was isolated from cells using an
RNeasy kit (Qiagen) and then reversed transcribed to produce cDNA
libraries with an iScript Select kit (Bio-Rad), both of which were
utilized according to the manufacturers’ suggested protocols. Three
separate biological replicates of cells in each condition were analyzed
by quantitative PCR (qRT-PCR) using intron-spanning primers tar-
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geted to the mRNAs for NSF and the ribosomal housekeeping gene
RPL13A. Sequences for these primers are as follows: NSF-forward:
GGCTTACTGGTGAAGGACATT; NSF-reverse: TTCCAACAACCAGTCCTACTTC; RPL13A-forward: TAAACAGGTACTGCTGGGCCGGAA; RPL13A- reverse: AAGGGTTGGTGTTCATCCGCTT.
RT-PCR was carried out in an ABI 7500 thermocycler using 2⫻
SYBR Green mix with ROX reference dye (Bio-Rad). The Ct values
for each gene were determined by selecting the threshold of SYBR
Green fluorescence at half intensity of the logarithmic phase of
amplification. The ratio of NSF/RPL13A mRNA abundance was then
determined for each sample to normalize relative gene expression, and
the level of expression for control cells (HK2 with nontargeting
shRNA) was set to 100%. Expression of NSF mRNA in cells with
NSF or LRRK2 knockdown was compared relative to this standard.
Statistical analysis. Each experiment with triplicate samples was
repeated a minimum of three times to ensure that results could be
replicated. Data reporting enzymatic rates were analyzed with GraphPad Prism 6 software for line fitting, with statistical significance
determined by a two-tailed t-test. Statistical significance is reported at
P ⬍ 0.05 or P ⬍ 0.01 as indicated in the figures.
RESULTS

Depletion of LRRK2 in human renal epithelial cells promotes vesicular accumulation. Consistent with several prior
studies, we found that histological staining of renal tissue from
Lrrk2⫺/⫺ mice at 3 mo of age reveals the accumulation of
optically clear vesicular inclusions within the cytoplasm of
cortical tubule epithelia (Fig. 1A). These inclusions are most
prominent in the proximal tubule cells, which can be identified
by their intraluminal brush border that is absent in distal tubule
cells. To determine whether human cells derived from renal
proximal tubule epithelia display similar defects in the absence
of LRRK2, we stably infected an immortalized human cell line
derived from this tissue with a lentiviral vector (pLKO.1) that
expresses a previously validated shRNA targeted to the LRRK2
mRNA (23). As a control, HK2 cells were also transduced with
a nontargeting shRNA that lacks homology to the human
coding genome. Simple phase-contrast microscopy of these
cells demonstrates a notable increase in the percent of cells
bearing large vesicular inclusions, many of which have prominent vacuole-like structures (Fig. 1B).
Given the wide range of vesicular trafficking phenomena
that have been associated with LRRK2 function in various
cellular and whole animal models, we sought to determine the
identity of the large vacuole-like structures that were frequently observed in the LRRK2-knockdown line of HK2 cells.
We used immunofluorescent staining with a variety of specific
antibodies that mark specific vesicular populations or organelles in the mammalian cell as indicated in Fig. 1C. We
particularly focused on markers that elucidate the autophagic,
endo-lysosomal, and recycling pathways for vesicular trafficking, all of which have been related to defects in LRRK2
activity.
Immunofluorescent imaging of LRRK2-deficient and control cells showed no obvious defects in the early endosome
(Fig. 1D) or autophagic pathways (Fig. 1E), though significant
differences in localization of late endosome/lysosomal (Fig.
1F) and Golgi markers (Fig. 1G) were apparent. Specifically,
we found that roughly 70% of cells contained large, perinuclear vacuole-like inclusions uniformly stained positive for the
late endosome marker Rab7 and that these inclusions were

typically situated in the perinuclear region of cells next to
LAMP1-positive lysosomes (Fig. 1, F and H). These observations are consistent with a role for LRRK2 in vesicular sorting
in renal epithelia, most likely in a postendocytic compartment
associated with cargo trafficking from the Rab7-positive late
endosome to the lysosome.
Depletion of LRRK2 in human renal epithelial cells causes
Golgi fragmentation. In addition to the vesicular accumulation phenotype noted above, immunofluorescent staining of
LRRK2-deficient cells also revealed widespread Golgi fragmentation (Fig. 1G). Markers for distinct compartments of the
Golgi (STX6 and GM130) were distributed over a larger area
of the cell with an average size of nearly 2.5 times that found
in control cells (Fig. 1I). Although this expansion and fragmentation of the Golgi apparatus was apparent in all LRRK2deficient cells, it was especially prominent in those that also
displayed an enlarged Rab7-positive endosomal compartment
(Fig. 1J). In contrast, the relatively small percentage of control
cells that contained an enlarged Rab7-positive endosomal compartment showed no difference in average Golgi area compared
to those with typical Rab7 staining (Fig. 1J).
To determine whether the expansion of the Golgi compartment was more specifically related to a loss of LRRK2 kinase
activity, we treated cells with two selective LRRK2 kinase
inhibitors (GNE-7915 and PFE-475) before imaging of the
Golgi apparatus by immunofluorescent microscopy. Immunoblot analysis of total protein levels and the autophosphorylation
site at S935 demonstrate that both drugs confer kinase inhibition up to 24 h with little impact on protein stability (Fig. 2, A
and B). Cells treated for 24 h with each drug were subsequently
imaged after staining cells with the Golgi markers STX6 and
GM130 (Fig. 2C). In contrast to the effect of complete LRRK2
knockdown with shRNA, we observed few cells with complete
Golgi fragmentation when LRRK2 kinase activity was pharmacologically blocked. We did, however, observe a milder
expansion of the Golgi apparatus, which was still significantly
enlarged compared with vehicle (DMSO)-treated cells (Fig.
2D). These data suggest that the Golgi expansion phenotype
observed after stable genetic depletion of LRRK2 is at least in
part a result of its kinase activity being absent in HK2 cells but
that absence of protein, or a longer timeframe, may be required
to elicit complete Golgi fragmentation.
Genetic depletion of NSF phenotypically mimics lrrk2 knockdown. Prior studies of LRRK2 function in neuronal vesicular trafficking identified the protein NSF as an interaction
partner and target of LRRK2 kinase activity (7, 31). This
finding is intriguing because NSF has been previously
shown to play a key role in the disassembly and reassembly
of Golgi stacks during and after mitosis, respectively (28,
32). The former role depends upon its ATPase activity,
whereas the latter occurs independent of its known enzymatic function. Cellular depletion of NSF in epithelial cells
promotes Golgi fragmentation and defects in receptor recycling, though it has little effect on cell viability or endocytosis (11). Given the defects seen in LRRK2-deficient HK2
cells, these data suggested a functional link between NSF
and LRRK2 in renal epithelia.
To test this hypothesis, we stably infected HK2 cells with an
shRNA that targets NSF and compared the phenotype of these
cells with LRRK2 knockdown (Fig. 3). Immunofluorescent
staining for the early and late endosomal compartments in

AJP-Renal Physiol • doi:10.1152/ajprenal.00009.2018 • www.ajprenal.org
Downloaded from journals.physiology.org/journal/ajprenal at Calvin College Seminary (153.106.212.096) on June 4, 2022.

F1469

LRRK2 DEFICIENCY IMPAIRS VESICLE TRAFFICKING IN TUBULE CELLS

A

B
20x

40x

C
Plasma membrane

NT-sh

Lrrk2+/+

Early endosome

EEA1
Sorting endosome

Rab5

Recycling
Rab7

STX6

LRRK2-sh

Late endosome

Autophagosome

LC3B

MVB

TGN

Lysosome

Lrrk2-/-

Degradation

gm130

LAMP1

Golgi

D

NT-sh

F

LRRK2-sh

Rab5
EEA1

NT-sh

LRRK2-sh

Rab7
LAMP1

20 Pm

20 Pm

E

G
STX6
GM130

LCB3
p62

I

80
70
60
50
40
30
20
10
0

J

**

golgi area (Pm2)

**

golgi area (Pm2)

% positive cells

H

250
200
150
100
50
0

NT

LRRK2

NT

LRRK2

**
350
300
250
200
150
100
50
0

**
(-) Rab7 vacuole

*

NT

(+) Rab7 vacuole

LRRK2

Fig. 1. LRRK2 deficiency disrupts vesicular trafficking in renal epithelia. A: H&E images of the renal cortex of wild-type (Lrrk2⫹/⫹) and knockout (Lrrk2⫺/⫺)
mice at 3 mo of age. B: bright-field images of normal human kidney (HK2) cells stably transduced with vectors expressing nontargeting (NT-sh) and LRRK2
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these cells demonstrates the presence of Rab7-positive vesicular inclusions that are phenotypically similar to those seen
after stable LRRK2 knockdown (Fig. 3A). Further characterization of the two knockdown lines by transmission electron
microscopy revealed an increase in the number and size of
electron-dense vesicular structures, which are characteristic of

late endosomes and lysosomes, compared with control cells
(Fig. 3B). The contents of these vesicles include whole organelles, membrane whorls, and electron-dense aggregates, suggesting that these represent endocytosed or autophagic material
that is destined for lysosomal degradation but has failed to be
properly digested (Fig. 3, C and D).
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LRRK2 and NSF physically and functionally interact in
renal epithelial cells. The similarity in phenotypes between
cells lacking either LRRK2 or NSF prompted us to investigate
whether the two proteins colocalize to the same compartment
in HK2 cells using confocal microscopy. Because endogenous
LRRK2 is found at very low levels in cultured HK2 cells, we
expressed exogenous FLAG-LRRK2 under control of the human EF1a promoter to facilitate immunofluorescent detection
(Fig. 4A). As a positive control, we first stained cells for total
LRRK2 versus the FLAG epitope to show that signals overlapped in the expected pattern (Fig. 4B). After confirming a
strong overlap correlation between these signals, we then
stained and imaged cells for the FLAG epitope versus endogenous NSF, which also demonstrated statistically significant
overlap by confocal microscopy (Fig. 4, A and B). It is notable
that NSF was detected on all vesicles that stain positive for
LRRK2, though a sizable portion of NSF-positive vesicles do
not appear to contain LRRK2 (Fig. 4A, inset). This observation
suggests that NSF is likely to play a broader role in vesicular
trafficking events than LRRK2, which appears to be more
restricted in its subcellular localization.
The relevance of LRRK2-NSF colocalization in cells is
reinforced by results of coimmunoprecipitation experiments
that demonstrate that NSF can be precipitated with endogenous
LRRK2 in HK2 cells (Fig. 4C). The interaction between these
two proteins is enhanced by addition of the NSF inhibitor
N-ethylmaleimide (NEM) to cell lysis buffer, which effectively
locks NSF into its homohexameric, ATP-bound state by inhibiting ATPase activity (8, 27). These findings demonstrate that
LRRK2 and NSF physically interact in renal epithelia and
suggest that these two proteins are functionally related to each

other in the process of vesicular trafficking in the endolysosomal system.
A potential insight into how LRRK and NSF interact became
apparent from monitoring levels of endogenous NSF in HK2
cells that stably expressed an shRNA targeted to LRRK2. We
observed that stable knockdown of LRRK2 leads to a roughly
40% decrease in NSF at both the mRNA and protein levels
(Fig. 4, D and E). Precisely why endogenous NSF expression
at the mRNA level would be decreased by LRRK2 depletion is
unclear, though we suggest it is an indirect relationship because overexpressing LRRK2 at a variety of levels using a
pseudotyped baculovirus system (BacMam) fails to increase
NSF levels (Fig. 4F). Furthermore, exogenous reexpression of
V5-tagged human NSF in cells with LRRK2 deficiency fails to
rescue the Golgi expansion defect seen when LRRk2 is depleted (Fig. 4E, data not shown). Together, these data support
the possibility of a functional link between LRRK2 and NSF
but exclude a mechanism in which LRRK2 simply regulates
NSF protein levels in the renal epithelia.
Golgi fragmentation after NSF or LRRK2 depletion occurs
independent of cell division. Because prior studies from our
laboratory showed a decrease in cellular proliferation rate
when LRRK2 is stably depleted from renal cancer cells, we
asked the question of whether the effect of LRRK2 knockdown
on Golgi structure in normal HK2 cells is simply an artifact of
mitotic arrest (23). To answer this question, we performed
pulse-chase labeling of cells with the thymidine analog EdU
and subsequently fixed and stained them for incorporation of
this marker using fluorescent click chemistry along with immunofluorescent staining for the Golgi marker GM130 (Fig. 5A).
EdU incorporation provides a good proxy for S-phase entry in
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Fig. 3. Depletion of NSF phenocopies LRRK2 deficiency and results in the accumulation of vesicular waste cargo. A: confocal immunofluorescent images
of HK2 cells transduced with nontargeting shRNAs or shRNAs targeted to LRRK2 or NSF. Cells were stained with antibodies for endogenous EEA1 (red)
and Rab7 (green) to indicate the early and late endosomal compartments, respectively. DAPI (blue) costain of nuclei is also shown in the merged image.
B–D: transmission electron microscopy was performed on dissociated cell pellets of HK2 cells that were stably depleted of LRRK2 or NSF using lentiviral
shRNAs. B: whole cell images of stable lines showing the accumulation of electron-dense vesicles in HK2 cells after depletion of LRRK2 or NSF. Cells
also displayed large vacuolar inclusions in some instances (red arrows). C: vesicles in HK2 cells lacking LRRK2 display whole organelles encased in
vesicles (black arrows), which suggest that some of these vesicles may be autophagic in origin. D: higher magnification images of LRRK2-deficient HK2
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undetermined identity. LRRK2, leucine-rich repeat kinase 2; HK2, normal human kidney cells; NSF, N-ethylmaleimide-sensitive fusion protein; shRNA,
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cells, which showed little difference when either LRRK2 or NSF
was knocked down in HK2 cells (Fig. 5B). Importantly, EdU
incorporation had no impact on Golgi size in control cells, though
depletion of either LRRK2 or NSF again caused an expansion in
the gm130-positive Golgi compartment (Fig. 5C).
To evaluate whether the effect of LRRK2 and NSF on Golgi
fragmentation occurred concomitant with cell cycle progression, we performed two experiments. In the first experiment,
we pulse-labeled cells with EdU for 2 h and then immediately
fixed and stained them for GM130. In this context, control cells
with EdU incorporation showed a small but insignificant increase in Golgi size, whereas LRRK2- and NSF-depleted cells
showed no difference, though their overall Golgi area was still
significantly larger than that of control cells (Fig. 5D). These

data show that while in S-phase before mitotic Golgi fragmentation has occurred cells lacking LRRK2 or NSF already have
expanded Golgi compartments.
In the second experiment, we performed EdU pulse labeling
as before but followed that with a 6-h medium chase to allow
for cells to progress through S-phase and into mitosis. Here we
observed a significant expansion of the Golgi area in EdUpositive cells, consistent with a mitosis-associated fragmentation of the Golgi (Fig. 5E). Importantly, however, we also
found that EdU-negative cells from the LRRK2- and NSFdepleted lines still displayed significantly expanded Golgi
compartments, indicating that loss of these two proteins leads
to a loss of Golgi compaction independent of progression
through S-phase and into mitosis.
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Depletion of LRRK2 and NSF impairs trafficking of endocytic cargo. A previous study of HeLa cells after knockdown
of NSF suggested that although endocytosis itself was unimpaired, the ability of cells to recycle endocytosed receptors
back to the cell surface was blocked by the absence of NSF
(11). We recapitulated these findings in HK2 cells using
fluorescently labeled dextran as a marker for fluid phase bulk
endocytosis and labeled transferrin as a marker for receptormediated endocytosis. After knockdown of LRRK2 or NSF,
we observed no change in the rate of dextran uptake relative to
control cells, which is consistent with the absence of a general
endocytic defect (Fig. 6, A and B). In contrast, the rate of
transferrin uptake was significantly decreased when either of

these proteins was depleted from HK2 cells (Fig. 6C). Because
the continuous uptake of transferrin by its receptor (TfR)
requires postendocytic recycling, this finding suggests that
both LRRK2 and NSF are required to maintain the recycling
pathway after internalization of membrane cargo from the cell
surface.
We next asked whether the late endosomal defect we first
observed in HK2 cells lacking LRRK2 could be a result of
improper sorting of endocytic cargo to the lysosomal compartment. In this context we used syntaxin-7 (STX7) as a positive
control because this protein is required for proper transport of
late endosomal proteins to the lysosome (29). As expected,
knockdown of STX7 had no impact on uptake of dextran or
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transferrin, though it significantly decreased trafficking of a
fluorogenic peptide substrate (BZiPAR) to the lysosomal compartment (Fig. 6, A–D). A similar decrease in trafficking of this
peptide was elicited by pretreatment of cells with the inhibitor
dynasore (30 M), which prevents dynamin-mediated scission
of endocytic vesicles (Fig. 6D). Interestingly, we found that
LRRK2 depletion resulted in a roughly 25% increase in peptide
trafficking rate to the lysosome, whereas depletion of NSF had
no effect. This finding suggests that the waste accumulation
defect seen in Lrrk2⫺/⫺ mouse kidneys and in HK2 cells after
LRRK2 knockdown may not be a result of decreased lysosomal trafficking per se but rather a loss of lytic activity toward
specific lysosomal substrates.
Depletion of LRRK2 and NSF impairs trafficking of lysosomal hydrolases. The finding that postendocytic lysosomal
sorting was normal, if not accelerated, in LRRK2 deficient

cells prompted us to examine whether the two central vesicular
trafficking defects seen upon LRRK2 or NSF depletion (expansion of the late endosome and fragmentation of the Golgi
apparatus) are functionally related by a defect in trans-Golgi to
late endosome transport. Among the various cargoes of interest
in this pathway are a variety of lysosomal hydrolases, which
are initially produced in the secretory pathway but then sorted
to the endosome rather than being secreted outside the cell.
Pharmacologic or genetic collapse of the trans-Golgi is known
to impair this process and to result in defective lysosomal
function (17).
Defects in trans-Golgi to late endosome transport can be
evaluated by measuring the steady-state ratio of lysosomal
hydrolases in the lysosome versus the secretory pathway;
defective sorting results in decreased lysosomal enzyme content and increased secretory pathway content. We used density-
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dependent organelle fractionation of hypotonically lysed cells
to isolate the lysosomal (P2) and microsomal fractions (P3) and
then performed immunoblotting for various proteins known to
traffic to the lysosome. Three such proteins (LAMP1, GBA,
and ARSB) show decreased abundance in the lysosomal fraction and/or increased abundance in the microsomal fraction of
cells deficient in LRRK2 and NSF compared with control cells
(Fig. 6E). These data were reinforced with a quantitative
enzymatic assay for N-acetylglucosaminidase (NAG) activity,
which is mediated by the lysosomal enzyme hexosaminidase-B. Data from this assay also showed increased NAG
activity in the microsomal fraction and decreased activity in the
lysosomal fraction of cells deficient in LRRK2 and NSF
compared with control cells (Fig. 6F). Together, these data
imply that the undigested waste material seen in cellular
vesicles by electron microscopy (Fig. 3, B–D) accumulates
because of insufficient trafficking of digestive hydrolases to the
lysosome due to trans-Golgi fragmentation.
In contrast to the defects in endocytic recycling, we did not
find any evidence of acute defects in autophagic flux in HK2
cells after knockdown of LRRK2 or NSF. Cells starved of
amino acids to induce autophagy demonstrated proper accumulation and subsequent turnover of LC3B and p62/SQSTM1
protein over a 10-h timecourse, suggesting that macroautophagy itself is not defective when LRRK2 or NSF is depleted
from HK2 cells (Fig. 6, G–J).
DISCUSSION

The discovery of PD-associated mutations in the gene encoding LRRK2 in 2004 produced a surge of interest in how this
protein works at the cellular level (30, 39). In the years since
that discovery, a wealth of research has demonstrated that
LRRK2 primarily functions as a regulator of vesicle trafficking
in a variety of cell types, including neurons, immune cells, and
in specific epithelial cell populations. Of these latter cell types,
Type II pneumocytes of the lung and proximal renal tubule
cells have received the most attention due to their especially
high expression of LRRK2 and their pathophysiological deficits upon Lrrk2 deletion in rodent models (4, 19). Prior studies
of these animal models have demonstrated the progressive
accumulation of undigested cellular contents within a poorly
defined vesicular compartment that bears features of the late
endosome, lysosome, and autophagosome (37, 38).
Precisely how and why this population of vesicles accumulates in the renal epithelium has been of significant interest for
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three reasons. In the first place, identification of the molecular
defects in these cells could potentially provide insights into the
cellular pathophysiology of neurons in Parkinson’s disease,
thereby providing new therapeutic targets for treatment. Second, identification of peripheral disease markers in patients
bearing LRRK2 mutations could potentially provide a means
for noninvasive monitoring of disease progression and response to therapy via urine sampling, which is far more
tractable than cerebrospinal fluid or tissue sampling (13).
Finally, the observation that genetic deletion of Lrrk2 in mice
leads to significant pathology in the lung and kidney suggested
that prolonged systemic treatment of PD patients with pharmacologic inhibitors of LRRK2 enzymatic activity could be
toxic to these organs, thus obviating this approach as a therapy
in PD. Although the realization of this concern has varied
among the various LRRK2 inhibitors developed to date, it
remains a significant issue given that patients treated in such
fashion could conceivably be dosed for decades because of the
chronic and progressive nature of PD (10, 18).
In this study we developed a cellular model of LRRK2
deficiency in normal immortalized human kidney cells derived
from the proximal tubule, which is primarily where LRRK2 is
expressed in the kidney (23). These cells phenocopy the early
renal defects seen in Lrrk2⫺/⫺ mice, including the presence of
an enlarged late endosomal compartment and accumulation of
vesicles with undigested lysosomal cargo. Most importantly,
we demonstrate that the LRRK2-NSF interaction is conserved
in human kidney cells and that loss of LRRK2 leads to a
compensatory destabilization of NSF and Golgi fragmentation.
Trafficking of cargo to and from the Golgi is consequently
disrupted by loss of either LRRK2 or NSF, suggesting that the
molecular interaction between these two proteins is critical for
the maintenance of vesicular trafficking homeostasis in the
kidney.
These findings provide important insights into the etiology
of endo-lysosomal dysfunction in cells with deficiency or
inhibition of LRRK2 by profiling the various vesicle trafficking
defects in these cells. Though prior studies both in vitro and in
vivo have noted the defects in Golgi organization associated
with LRRK2 deficits, they did not functionally connect these
defects to the accumulation of undigested waste vesicles that
are also observed in these cells (21, 22). Here we show that the
fragmentation of the entire Golgi apparatus in LRRK2-deficient cells leads to deficits in trans-Golgi to lysosome trafficking, including the trafficking of important lysosomal hydro-

Fig. 6. LRRK2 deficiency alters the balance of vesicular trafficking between the late endosome and downstream compartments. A: immunoblot for LRRK2, NSF,
STX7, and tubulin in lysates of stable HK2 lines transduced with shRNA vectors to the indicated genetic target (NT, nontargeting). B: time course of fluid-phase,
bulk endocytosis in stable HK2 lines by measuring uptake of AlexaFluor-488 labeled dextran. C: time course of receptor-mediated endocytosis by measuring
uptake of AlexaFluor-488 labeled transferrin. Continuous uptake of transferrin depends upon recycling of the transferrin receptor from endosomes through the
trans-Golgi network to the plasma membrane (*P ⬍ 0.05 relative to NT control). D: quantification of endocytic trafficking to the lysosome as a function of
BZiPAR peptide uptake and conversion by lysosomal peptidases in the indicated HK2 stable lines. The dynamin inhibitor dynasore (30 M) was added 15 min
before BZiPAR (50 M). (*P ⬍ 0.05). E: immunoblot of the lysosomal proteins LAMP1, GBA, and ARSB isolated by differential centrifugation from the
indicated HK2 stable lines. P2, lysosomal pellet; P3, microsomal pellet. F: quantification of N-acetylglucosaminidase (NAG) activity in the lysosomal and
microsomal fractions of stable HK2 cell lines. Error bars indicate standard deviations of three replicates (*P ⬍ 0.05). G–J: immunoblot analysis of lysates from
the indicated stable HK2 cell lines after a time course treatment of amino acid starvation in the presence or absence of bafilomycin A1 (BafA1, 50 nM).
Autophagic flux was monitored by the decreases in the adaptor protein SQSTM1 (p62) and the turnover in LC3B generated by induction of macroautophagy.
Individual panels show the time course results for controls cells infected with lentivirus containing a nontargeting shRNA (G) or shRNAs targeting LRRK2 (H),
NSF (I), or STX7 (J). Actin levels were included to indicate equal loading of each sample. BZiPAR, Rhodamine 110, bis-(CBZ-L-isoleucyl-L-prolyl-L-arginine
amide), dihydrochloride; LRRK2, leucine-rich repeat kinase 2; HK2, normal human kidney cells; NSF, N-ethylmaleimide-sensitive fusion protein; shRNA, short
hairpin RNA; STX, syntaxin.
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lases. Collectively, these data implicate defects in Golgi apparatus organization and structure as the primary cause for
lysosomal dysfunction in renal cells lacking LRRK2.
In this context, it is worth noting that genes whose absence
or mutation cause similar defects in protein trafficking have
previously been associated with PD, including the genes encoding glucocerebrosidase (GBA) and the retromer complex
component VPS35 (9, 25). Whether this implies a general
mechanism for the onset of cellular toxicity in PD is unclear at
this time, particularly because the relationship of lysosomal
dysfunction to the other cardinal hallmarks of PD (mitochondrial dysfunction and alpha-synuclein aggregation) remains
somewhat obscure (9). Given the growing number of vesicle
trafficking proteins that have been connected to this disease,
however, the ongoing search for a unifying mechanism is of
considerable importance.
One final point of interest regarding LRRK2 and human
disease should be noted in the context of renal cancer. Both we
and others have implicated LRRK2 amplification and hyperactivity in the type I subset of papillary renal cell carcinomas
that account for ~10% of all human kidney cancer (2, 23). We
speculate that these tumors, which are driven by aberrant
receptor tyrosine kinase signaling through the hepatocyte
growth factor receptor MET, may select for LRRK2 amplification (chromosome 12q12) to promote mistrafficking of MET
away from lysosomes and toward the endosome-to-Golgi recycling pathway. Given that LRRK2 knockdown seems to
enhance the rate of trafficking from endosomes to the lysosome, it is possible that the converse event (hyperactivation of
LRRK2 activity) would slow trafficking of endocytic cargo to
the lysosome, leading to aberrant stabilization of MET. We
intend to address this question in future studies as a means of
providing insights into the molecular events leading to cellular
transformation in the human kidney.
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